SHIRE LLC innovation strategy

Patent filings in countries

#	Country	Total Patents
#1	United States	88
#2	EPO (European Patent Office)	49
#3	United Kingdom	48
#4	Australia	40
#5	WIPO (World Intellectual Property Organization)	33
#6	Canada	31
#7	China	29
#8	Brazil	25
#9	Republic of Korea	24
#10	Israel	22
#11	Mexico	15
#12	Japan	9
#13	New Zealand	7
#14	EAPO (Eurasian Patent Organization)	4
#15	South Africa	4
#16	African Regional Industrial Property Organization	3
#17	Argentina	3
#18	Singapore	3
#19	Taiwan	3
#20	Hong Kong	2
#21	Malaysia	2
#22	Norway	2
#23	Colombia	1
#24	Costa Rica	1
#25	Egypt	1
#26	Iceland	1
#27	Netherlands	1
#28	Ukraine	1

#	Industry
#1	Pharmaceuticals
#2	Organic fine chemistry
#3	Machines
#4	Environmental technology
#5	Biotechnology
#6	Micro-structure and nano-technology

#	Technology
#1	Therapeutic chemical compounds
#2	Medical preparations
#3	Heterocyclic compounds
#4	Acyclic or carbocyclic compounds
#5	Unspecified technologies
#6	Unspecified technologies
#7	Organic chemistry methods
#8	Climate change adaptation technologies
#9	Peptides
#10	Nanostructure applications

Publication	Filing date	Title
US2015080474A1	2014-09-26	Controlled dose drug delivery system
WO2014144115A1	2014-03-14	Fixed dose combination treatment for schizophrenia
WO2014168727A1	2014-03-14	Fixed dose combination treatment for schizophrenia
US2014178467A1	2014-02-28	Capsule and powder formulations containing lanthanum compounds
GB201314960D0	2013-08-21	Heterocyclic derivatives
GB201314965D0	2013-08-21	Spirocyclic derivatives
GB201314961D0	2013-08-21	Spirocyclic derivatives
GB201204590D0	2012-03-15	Prodrugs of thiazolamine compounds
GB201204589D0	2012-03-15	Prodrugs of guanidine compounds
GB201204587D0	2012-03-15	Prodrugs of guanidine compounds
WO2012085586A1	2011-12-22	Mexiletine prodrugs
CN105943554A	2011-11-30	Capsule and powder formulations containing lanthanum compounds
WO2012056246A1	2011-10-28	Combination treatment of major depressive disorder
WO2012046062A1	2011-10-05	Use of prodrugs to avoid gi mediated adverse events
AU2011303610A1	2011-09-14	Prodrugs of guanfacine
GB201115380D0	2011-09-06	Prodrugs of methotrexate and related compounds and uses thereof
EP2739140A1	2011-07-29	Homoarginine prodrugs and/or conjugates of amphetamine and other stimulants and processes for making and using the same
GB201112081D0	2011-07-14	Prodrugs of non-opioids and uses thereof
GB201112082D0	2011-07-14	Prodrugs of pharmaceologically active phenolic drug metabolites and uses thereof
GB201112080D0	2011-07-14	Prodrugs of opioids and uses thereof